UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No)*
KalVista Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, \$0.001 par value
(Title of Class of Securities)
483497103
(CUSIP Number)
December 31, 2017
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

þ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

1. NAMES OF REPORTING PERSONS						
	Eventide Asset Management, LLC					
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)						
	(a) \square	>)				
	(a) □ (b) □					
3. SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION					
Delaware						
	Bolawaro					
		5.	SOLE VOTING POWER			
			709,000			
\!! !\		6.	SHARED VOTING POWER			
N	UMBER OF SHARES					
ВЕ	NEFICIALLY		0			
	NED BY EACH	7.	SOLE DISPOSITIVE POWER			
REPORTING PERSON WITH						
		8.	709,000 SHARED DISPOSITIVE POWER			
		ο.	SHARED DISPOSITIVE POWER			
			0			
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	700.000					
10.	709,000 CHECK IF THE	AGC	GREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
	(see instructions)					
11.	PERCENT OF (CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)			
	0.007					
12.	6.6% TYPE OF REPORTING PERSON (see instructions)					
12. THE OF INDICATING FEITOON (SEE INSURCIONS)						
	IA					

Item 1.

- (a) Name of Issuer KalVista Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142

Item 2.

- (a) Name of Person Filing Eventide Asset Management, LLC
- (b) Address of the Principal Office or, if none, residence One International Place, Suite 3510, Boston, MA 02110
- (c) Citizenship Delaware
- (d) Title of Class of Securities Common Stock, \$0.001 par value
- (e) CUSIP Number 483497103

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	þ	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)		Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 709,000

(b) Percent of class: 6.6%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 709,000

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 709,000

(iv) Shared power to dispose or to direct the disposition of: 0

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 3510, Boston, MA 02110 is the beneficial owner of 709,000 common shares, as of December 31, 2017, by virtue of being the investment adviser to registered investment companies (mutual funds). All 709,000 common shares, which represents 6.6% of the issuer's outstanding common shares, were held by the Eventide Healthcare & Life Sciences Fund.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

EUSIP No. 483497103	13G	Page 5 of 5 Pages
em 10. Certification.		
course of business and were not acquired and are not held for the	elief, the securities referred to above were acquired and are held in e purpose of or with the effect of changing or influencing the control on with or as a participant in any transaction having that purpose or	of the issuer of
After reasonable inquiry and to the best of my knowledge and lorrect.	belief, I certify that the information set forth in this statement is true, (complete and
	02/12/2018	
	Date	
	/s/ Peter J. Luiso Signature	
	•	

Peter J. Luiso, Chief Compliance Officer and General Counsel Name/Title